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A series of contrast agents for magnetic reso-
nance imaging (MRI) aimed at noninvasively
determining the hormone receptor status of
cancer in vitro was developed. These MRI con-
trast agents were prepared by conjugating pro-
gesterone to clinically used Gd(III) chelates.
These agents exhibited higher progesterone re-
ceptor binding affinities in the nanomolar range
and intracellular accumulation. High logP
values of the modified compounds suggested
that the lipophilicity of the steroid conjugates
may have contributed to membrane permeabil-
ity. Synchrotron radiation X-ray fluorescence
microscopy and magnetic resonance images
revealed that the synthesized conjugates
showed the greatest cellular accumulation and
significant increase in relaxivity in vitro com-
pared to the previously developed steroid-
modified agent. Transcriptional assays using
the progesterone response element linked
to luciferase indicated that the contrast agents
entered the cell, interacted with the biological
target, and drove specific progesterone-
mediated transcription.
INTRODUCTION
Magnetic resonance imaging (MRI) has become an impor-
tant tool in the clinical diagnosis of diseases. Images are
acquired by employing radio frequency pulses to excite
nuclear spins of a specimen and imposing one or more or-
thogonal magnetic field gradients [1, 2]. The observed sig-
nal is from the protons of water molecules, where signal in-
tensity in a given volume element is a function of the water
concentration and relaxation times (T1 and T2) [3]. Optical824 Chemistry & Biology 14, 824–834, July 2007 ª2007 Elseviemicroscopy of opaque specimens is limited by light scat-
tering, whereas MRI can image in three dimensions with
high spatial and temporal resolution [4, 5]. Intrinsic MR
contrast can be enhanced by using agents that modulate
the spin-lattice relaxation rates of water protons [6]. Para-
magnetic ions such as Gd(III) are routinely used to de-
crease the local T1 relaxation of nearby water protons,
and when chelated are nontoxic contrast agents [6].
A barrier to the further development of MRI as a diagnos-
tic tool is the lack of targeted contrast agents. New clas-
ses of bioactivatable agents have been prepared to
reduce background signal and possess two distinct states
(on and off) as a result of the absence or presence of
enzymes or secondary messengers [7–10]. Numerous
examples have been reported where the agents are
loaded into cells or conjugated to molecular targeting
platforms such as monoclonal antibodies [11]. However,
these approaches are limited by the ability of the agent
to be linked to an antibody without perturbing the recogni-
tion properties or limited by the amount of uptake into
cells. Therefore, targeted strategies for new generations
of chelates and ligands are required to improve cellular
permeability and specificity of MRI agents.
The progesterone receptor (PR) is a member of the
nuclear receptor superfamily that functions as a ligand-
activated transcription factor. Mammary epithelial cells
express the PR and estrogen receptor (ER) [12]. The PR
is present in two distinct isoforms both derived from the
same gene, PRA and PRB. Each subtype is critical to
mammary gland lobuloalveolar development and epithe-
lial differentiation [13]. The receptor consists of several re-
gions that serve as functional units such as the DNA bind-
ing domain, the ligand binding domain, and transcriptional
activation domains. The expression of these receptors is
a critical parameter typically examined using immunohis-
tochemistry in biopsies of human breast cancers [14, 15].
The presence of both receptors correlates with the sur-
vival rate of breast cancer patients [16]. The PR is an
estrogen-regulated gene that becomes activated and
expressed in the presence of estradiol and ER. It is notr Ltd All rights reserved
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correlates with tamoxifen resistance, although the mech-
anism of resistance is still debated [17]. Tumors that are
ER+/PR are considered more aggressive than PR+ tu-
mors and correlate with a lower survival rate [18, 19].
The current clinical methods to determine PR and ER
levels require tissue biopsy or radioisotope injection fol-
lowed by ionizing radiation. Therefore, noninvasively de-
termining whether or not a mammary cancer expresses
PR may be crucial to deciding the most effective chemo-
therapeutic agent for the patient.
As a result of the hydrophilic nature of Gd(III) chelates,
MR contrast agents do not traverse cell membranes and
are restricted to the extracellular domains [10, 20]. These
chelates are thermodynamically stable (Kd = 10
21
1025) and kinetically inert [6]. Steroids readily diffuse
across the phospholipid bilayer due to their hydrophobic
properties and small size [21]. Further, the availability of
receptor-specific hormones could determine whether
the steroid is retained within a specific cell type allowing
the cell, and not the contrast agent, to determine molecu-
lar targeting. The steroid progesterone is an endogenous
molecule with limited toxic activity and well-established
pharmacokinetic profiling [22]. In addition, steroids are
typically retained in the nucleus of cells once bound to
their receptor, where they interact with the DNA to drive
gene transcription. Contrast agents that bind to large
macromolecules such as enzymes or proteins undergo
a dramatic increase in the relaxation rate of nearby water
protons [1, 2]. Binding to a macromolecule increases
concentration and retention of the Gd(III) complex at the
receptor binding site and affords an increase in rotational
correlation time (tr) of the agent [6]. Therefore, progester-
one-Gd(III) chelate conjugates are an attractive choice for
use as MRI contrast agents that target hormone receptor-
positive cells [23].
Steroid-conjugated magnetic resonance contrast
agents are a rational design for generating targeted en-
hancement due to intracellular accumulation. As breast
tumors become more aggressive, they typically lose hor-
mone receptors and become less responsive to hor-
mone-based breast cancer therapies. Few methods are
available for imaging breast tumors in vivo, and none facil-
itate the molecular or therapeutic profiling of tumors.
Previously, RU-486-modified MR contrast agents were
proved to be membrane permeable, and successfully in-
teract with progesterone receptors in cells and provide
limited signal enhancement [23]. Therefore, the purpose
of this investigation was to develop Gd(III)-conjugated ste-
roid contrast agents that accumulate intracellularly, where
they might interact with nuclear progesterone receptors
and thereby increase magnetic resonance. By using a pro-
gesterone receptor targeted contrast agent, it may be
possible to visualize the morphology of organs and dis-
eased tissue and to determine the biochemical character-
istics of cells. Finally, a synthetic methodology has been
designed to prepare new MRI contrast agents that can
be targeted to other hormones for imaging of hormone-
dependent cancers [24].Chemistry & Biology 14,RESULTS
Design and Synthesis of Progesterone Receptor
Targeted MR Contrast Agents
A series of progesterone conjugates with Gd(III) contrast
agents was synthesized and characterized (Figure 1). Pre-
viously, RU-486 was modified with a similar Gd(III) chelate,
and it was discovered that the site of attachment was
critical to the binding affinity of the complex. The RU-
486-modified conjugate had approximately a 100-fold de-
crease in affinity for the receptor [23]. As a result of those
experiments, the labeling strategy was modified for the
synthesis of new progesterone agents. The 3-keto group
on the hormone is not an ideal modification site because
it interacts with a highly conserved region in the receptor
protein [25]. Therefore, modification or isomerism at this
site may compromise the binding affinity of the modified
steroid [26–28]. A number of alternatives to this site are
available and position 17 of the D ring was chosen.
A series of Gd(III) complexes was synthesized to exam-
ine the effect of charge on lipophilicity and cell permeabil-
ity of the conjugate (neutral,1, and2). Further, to deter-
mine the effect distance between the chelate and steroid
may have on receptor binding affinity, spacers with vary-
ing lengths (zero, three, and six methylene carbons)
were inserted between progesterone and the Gd(III)
chelate. The neutral series of conjugates with zero- and
six-carbon spacers (1, 2) was synthesized from 21-
hydroxyprogesterone, as shown in Figures 2A and 2B.
The synthesis of 1 began with bromination of the 21-
hydroxyl group using carbon tetrabromide and triphenyl-
phosphine. The attachment of 5 with K2CO3 (NBu4OH as
a catalyst) afforded the t-butyl-protected ligand (6) in
high yield (93%). After deprotection of the t-butyl group
by trifluoroacetic acid, the ligand was heated with Gd(III)
chloride at 60C to produce compound 1 in 72% yield.
The synthesis of 2 started with alkylation of the 21-
hydroxyl group by 1,6-dibromohexane. This biphasic
alkylation reaction produced bromine-tethered progester-
one (7) in 74% yield. A coupling reaction with DO3A
followed by insertion of the lanthanide was performed by
the same methods described in the synthesis of 2, with
58% yield.
The synthesis of the charged series of conjugates (3, 4)
begins with the bromine intermediates (5, 7) from the neu-
tral series (Figure 2C). In the first step, the bromine group
was substituted with an azide. After reducing the azide
with Lindlar’s catalyst, a coupling reaction of the free
amine with an isothiocyanate-Gd(III) chelate was attemp-
ted. However, when the pendant amine is neutral or in ba-
sic form, the product is unstable, producing a number of
uncharacterized byproducts. To circumvent this problem,
the azide group was reduced and protected with a Boc
group in one pot to give 13 and 14. After deprotection of
the Boc group using trifluoroacetic acid, the TFA salt of
amines was coupled with the charged Gd(III) chelates
(15 and 16) to produce 3 and 4, respectively. Chelates
possessing a 1 or 2 charge with no spacer (17 and
18) decomposed during preparative high-performance824–834, July 2007 ª2007 Elsevier Ltd All rights reserved 825
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Progesterone-Modified MRI Contrast AgentsFigure 1. Structures of Progesterone-Conjugated MRI Contrast Agentsliquid chromatography purification, and the structure of
these molecules was not determined. The charged Gd(III)
chelates (15 and 16) were synthesized from commercially
available ligands by previously published research [23].
Relaxivity and Octanol-Water Partition Coefficients
The relaxivity and octanol-water partition coefficients of
1–4 are presented in Table 1 and show that charged com-
plexes have higher relaxivities. This tendency is due to
aggregation caused by the amphiphilic nature of the
compounds. The evidence supporting complex aggrega-
tion is the high relaxivity of 3 (19.1 mM1s1) measured
in the range of 0.125–2 mM. However, when the solution
was diluted approximately 100-fold (concentration range
from 0.001 to 0.1 mM), the relaxivity decreased to
5.9 mM1s1.
The octanol-water partition coefficient (P) of each com-
pound was measured to determine lipophilicity. The P
value is often expressed in logarithmic form (logP), be-
cause the values usually range over many orders of
magnitude. The observed logP values of the progesterone
conjugates indicate that aggregation is occurring. Com-
pound 3 has approximately the same logP value as 1;
however, the relaxivities of these compounds are very
different (19.1 and 3.77 mM1s1, respectively). The
results indicate that the overall lipophilicity of the two
molecules is similar and that the charged species seem826 Chemistry & Biology 14, 824–834, July 2007 ª2007 Elsevieto be sufficiently amphiphilic to aggregate in solution.
In addition, cellular uptake studies show that unlike com-
mercially available Gd(III) contrast agents, such as Pro-
hance, these new steroid conjugates are membrane
permeable. Compared to Prohance (logP = 2) [29], all
conjugates have greater logP values, implying that lipo-
philicity of the molecules may contribute to membrane
permeability.
Steroid-Gd(III) Conjugates Bind to the Ligand
Binding Domain of Progesterone Receptor A
Modification of a steroid with a Gd(III) chelate may inter-
fere with the interaction of the steroid with its receptor.
To examine the effect of the modification, competitive
binding experiments were performed using increasing
doses of the contrast agents and fluorescently labeled
progesterone as the competitor. At least five doses for
each compound were used to determine the IC50 of
each compound for progesterone receptor. The results
are shown in Table 2. Relative binding of each progester-
one contrast agent can be compared to progesterone.
Compound 1 had the highest relative binding affinity for
the receptor of all the compounds and differed only
slightly from compound 3. Compound 2 had a relative af-
finity for the receptor that was about 100-fold lower than
progesterone alone, but this was still in the high nanomo-
lar range.r Ltd All rights reserved
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Progesterone-Modified MRI Contrast AgentsFigure 2. Synthesis of Progesterone-Modified Gd(III) Chelate Conjugates
(A) Synthesis of neutral conjugates containing no spacer between the steroid and contrast agent.
(B) Synthesis of neutral conjugates containing a six-carbon spacer.
(C) Synthesis of charged progesterone conjugates.Steroid-Based Contrast Agents Demonstrate
Accumulated Gd(III) Inside the Cell
To determine the cell permeability and toxicity of the com-
pounds, cellular uptake experiments were performed by
incubating the contrast agents with progesterone recep-
tor-positive (T47D) and progesterone receptor-negative
(MDA-MB-231) mammary epithelial cells. Dose-response
experiments were performed to identify the proper
concentration of contrast agents to accomplish cellular
accumulation. The cells were incubated with 50, 5, 0.5,
Table 1. Relaxivity Data and Octanol-Water Partition
Coefficients (LogP) of 1–4
Compound LogP Relaxivity (mM1s1)a
Progesterone 3.87b —
1 0.292 3.77/4.76c
2 0.262 4.73c
3 0.377 19.1/5.9d
4 0.959 6.5
Prohance 2.0 3.7e
a Data were measured at 60 MHz, 37C.
b Data were taken from Alvarez Nunez and Yalkowsky [29].
c Data were measured at 4.7 T, 21C.
d Data were measured at low concentration from 0.001 to
0.1 mM.
e Data were taken from Caravan et al. [6].Chemistry & Biology 14, 8or 0.05 mM agents for 24 hr with T47D and MDA-MB-
231 cells. The contrast agents were absorbed in a dose-
dependent manner and demonstrated maximal accumu-
lation at 50 mM (Figure 3A). Cells were incubated with
only 1 or 2 at different time points including 1, 2, 4, and
24 hr to determine the optimal incubation time for accu-
mulation. After incubation, the cells were lysed and sub-
jected to inductively coupled plasma mass spectrometry
(ICP-MS) analysis to quantify the number of Gd(III) ions
present in each cell based on milligrams of protein
(Figure 3B). Compound 2 showed the highest uptake
into the PR-expressing T47D cell line, and in cells lacking
PR, the MDA-MB-231 cell line. Compounds 3 and 4 had
much lower uptake, indicating that the negative charge
of the contrast agent reduces cellular permeability.
Table 2. Receptor Binding Affinity Results of 1–3
Compound IC50 (M)
Progesterone 1.6 3 109
1 9.6 3 108
2 4.6 3 107
3 8.6 3 107
RU-486a 2.2 3 108
RU-486-Gda 1.9 3 106
a Data were taken from Lee et al. [23].24–834, July 2007 ª2007 Elsevier Ltd All rights reserved 827
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Progesterone-Modified MRI Contrast AgentsFigure 3. Cellular Uptake Studies of Progesterone-Modified Contrast Agents
(A) Progesterone Gd(III) chelates are dose dependently absorbed into mammalian breast cancer cells that either express progesterone receptor or are
receptor negative. Cells were incubated with 50, 5, 0.5, or 0.05 mM contrast agents for 24 hr, washed with PBS, and lysed, and the amount of828 Chemistry & Biology 14, 824–834, July 2007 ª2007 Elsevier Ltd All rights reserved
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than 1, demonstrating the importance of the hydrophobic
carbon linker. To determine the cellular distribution of 1
and 2, synchrotron radiation X-ray fluorescence (SR-
XRF) analysis was performed. SR-XRF spectroscopy
uses high-energy X-rays to produce a map of each ele-
ment’s concentration with submicrometer resolution,
whereas conventional XRF analysis provides the elemen-
tal composition of materials. A major advantage of
SR-XRF over standard fluorescence microscopy is that
images are obtained without altering the agent by attach-
ment of an organic fluorophore [22]. Compounds 1 and 2
(50 mM) were incubated with progesterone receptor-
positive cells (T47D) and -negative cells (MDA-MB-231)
for 24 hr prior to scanning. The samples were raster
scanned at coarse resolution (2.0 mm 3 2.0 mm step
size). The images show accumulation of each compound
within cells and confirmed cellular uptake of 2 (see Sup-
plemental Data available with this article online).
Steroid-Based Contrast Agents Efflux More Slowly
from Receptor-Expressing Breast Cancer Cells
One aspect of molecular specificity that a steroid-based
contrast agent may provide is retention in cells expressing
the progesterone receptor. Because progesterone inter-
acts with its receptor and is active in the nucleus as a tran-
scription factor long after initial absorption, experiments
were designed to determine whether this would result in
a slower leaching of the contrast agents from progester-
one receptor-expressing T47D cells as compared to the
progesterone receptor-negative MDA-MB-231 cells. Cells
were incubated with 50 mM contrast agents for an initial
24 hr absorption period. The media containing the con-
trast agents were then removed, followed by three PBS
washes, and the cells were then allowed to leach the intra-
cellular portion of the contrast agent into serum-free me-
dia for 1, 2, 4, 6, 24, or 48 hr. The amount of the contrast
agents was then determined by quantifying the amount
of compound inside the cell using ICP-MS and then di-
vided by the amount of gadolinium in the leached media
minus the background (Figure 3C). Although 1 did not ap-
pear to leach from the MDA-MB-231 cells more quickly,
compound 2 showed much higher retention in the T47D
cell line as compared to MDA-MB-231. Therefore, one
way that these compounds may specifically mark proges-
terone receptor-positive cells is by residing in the cell
longer, due to interaction with PR.Chemistry & Biology 14Steroid Conjugates Function to Transcriptionally
Upregulate PRE-Luciferase
Progesterone receptors bind to a region of DNA referred
to as the progesterone response element (PRE). This
DNA element (repeated three times) was ligated to DNA
encoding the luciferase gene and used to (1) monitor the
cell permeability of the compounds, (2) verify the ability
to interact with the progesterone receptor dimer, and (3)
evaluate function in a transcription complex (Figure 4).
For the progesterone derivatives, induction of luciferase
indicated that the compound was functional. Each
compound showed the ability to alter transcription of the
PRE, indicating that it entered the cell and bound to the
full-length progesterone receptor. Agent 2 proved
the most effective transcriptional agent and differed mar-
ginally from compound 3 in its ability to bind to the recep-
tor. This indicates that a neutral charge on the agent is
beneficial for activity and permeability. A hydrophobic
linker between the progesterone molecule and the Gd(III)
chelate appeared to improve cell permeability and may in-
crease transcription, because the compounds are inside
the cell interacting with the progesterone receptor for
a longer period of time. These data confirm that although
compound 2 does not bind as readily to the PR as com-
pound 1, the improved cell permeability makes the agent
enter the cells more rapidly, at lower doses, and provides
higher transcriptional activity.
Steroid-Based Contrast Agents Enhance T1
Relaxivity In Vitro
To determine the effect of 1 and 2 on T1 after receptor
binding, we obtained T1-weighted images and measured
spin-lattice relaxation times of incubated cells (Figure 5A).
Compound 1 was chosen because of its high binding
affinity and compound 2 because of efficient cellular
uptake. Progesterone receptor-positive cells (T47D,
MDA-MB-231 transfected with PRA) and -negative cells
(MDA-MB-231) were incubated with 50, 150, and
500 mM 1 and 2 for 24 hr prior to scanning.
T1-weighted images and relaxation times show that
compound 2 enhanced MR contrast significantly more
than compound 1 in any given cell type. All cells that
were treated with compound 2 appeared much brighter
than the cells that were treated with compound 1 or con-
trol media. For example, cells exposed to 150 mM 2
reduced T1 more than 60% compared to controls. There
are no significant changes in T1 at 500 mM 2, indicatingintracellular Gd(III) was quantified using ICP-MS. Data represent the average of triplicate determinations divided by the amount of cellular protein to
normalize content based on cell number.
(B) Progesterone Gd(III) chelates are time dependently absorbed into mammalian breast cancer cells with and without progesterone receptors. Cells
were incubated with 50 mM contrast agents for 1, 2, 4, or 24 hr, washed with PBS, and lysed, and the amount of intracellular Gd(III) was quantified
using ICP-MS. Data represent the average of triplicate determinations divided by the amount of cellular protein to normalize content based on cell
number.
(C) Progesterone gadolinium chelates are selectively retained in progesterone receptor-expressing cells at specific time points after leaching into
culture medium. Cells were incubated with 50 mM contrast agents for 24 hr, washed with PBS at 0.5, 1, 2, 4, 6, 24, and 48 hr, lysed, and the amount
of intracellular and effluxed Gd(III) was quantified using ICP-MS. Data represent the average of triplicate determinations with the amount of Gd(III) in
the cell divided by the amount in the media and then divided by the amount of cellular protein to normalize content based on cell number (x axis,
incubation time; y axis, retention ratio)., 824–834, July 2007 ª2007 Elsevier Ltd All rights reserved 829
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Function Biologically to Initiate Gene
Transcription of a ProgesteroneRespon-
sive Element
T47D cells were transiently transfected with
the 33PRE-luciferase construct and serum
starved for 24 hr before treatment with contrast
agents for an additional 24 hr. Relative light
units were calculated and the data represent
the average ± the standard deviation from trip-
licate measurements.that the cells were saturated with compound 2 at 150 mM
and no further uptake occurred.
DISCUSSION
A flaw with currently available magnetic resonance con-
trast agents is their lack of intracellular accumulation,
limiting their specificity to extracellular compartments.
Proteins that reside inside the cell offer additional targets
for specificity. For hormone-dependent cancers, the
expression of progesterone receptor is one such target
and the conjugation of the gadolinium complex allows
for cell penetration. In this study, several novel MR agents
were synthesized and evaluated to target progesterone
receptors. The most promising agent, compound 2,
demonstrated hormone receptor binding, progesterone-
responsive gene transcription, and enhanced intracellular
relaxivity. Our results indicate that steroid receptor-
specific MR agents can be prepared and retain their ability
to interact with their receptor to enhance relaxivity.
The progesterone-MR contrast agent conjugates were
designed to optimize receptor interaction. A series of
agents was synthesized with variable linkers between
the Gd(III) chelate and the hormone backbone. The impact
of linker length on receptor interaction was examined us-
ing progesterone receptor binding experiments and sur-
prisingly demonstrated that the agents with the highest
affinity were those that had no spacer between the chelate
and hormone, such as compound 1. Because it has a hy-
drophilic Gd(III) chelate instead of having a lipophilic chain
on the 21 position, this might indicate that there is a favor-
able interaction between receptor protein and the chelate.
Altering the carbon chain with a hydrophilic PEG linker or
poly-amino acid chain may result in higher receptor bind-
ing affinity. The progesterone Gd(III) chelates had an ap-
proximately 100-fold higher affinity for this receptor than
the chelate conjugated to RU-486 [23]. Incorporating
a linker region between the steroid and the chelate re-830 Chemistry & Biology 14, 824–834, July 2007 ª2007 Elseviesulted in lower binding affinity for the receptor, perhaps
through disruption of dimer formation. The relatively tight
binding of the hormone with the receptor demonstrates
that the modification of the steroid decreases but does
not prohibit interaction with the progesterone receptors.
Conjugation of a Gd(III) chelate to the steroid progester-
one allowed for significant and rapid cellular accumulation.
All of the compounds traversed the cell membrane in
a dose-dependent manner. Conjugate 2 most readily en-
tered the cells, as indicated by ICP-MS and X-ray analysis.
Compound 1, however, was not as membrane permeable
as the compounds containing a six-carbon extended
spacer, likely due to its relatively low lipophilicity. The
addition of different charges on the chelate adversely
affected cell permeability, probably due to the inability of
the charged group to readily pass the hydrophobic mem-
brane. These experiments demonstrate that the steroid
conjugation of the Gd(III) chelate allows it to be carried
into the cell where it may interact with the progesterone
receptor.
Progesterone-conjugated Gd(III) chelates are cell
permeable and interact with the progesterone receptor,
suggesting they could provide cell-specific image en-
hancement. Activation of the specific biological target by
the contrast agent was directly demonstrated using the
transcriptional activation of the PRE-luciferase construct.
Transcriptional activation is important for specific cellular
targeting because the contrast agent would be engaged in
a receptor:DNA complex and might be retained within the
cell. By directly comparing the amount of gadolinium that
leached from progesterone receptor-expressing T47D
cells as compared to receptor-negative MDA-MB-231
cells, a relative retention was calculated. Compound 2
was specifically retained in receptor-expressing cells.
Compound 1 was not specifically retained, likely because
the initial absorption of the compound is relatively low.
Cellular retention is likely different between 1 and 2, due
to the enhanced interaction with the receptor after highr Ltd All rights reserved
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Progesterone-Modified MRI Contrast AgentsFigure 5. In Vitro MRI Results
(A) T1-weighted images of breast cancer cells incubated with compounds 1 and 2 for 24 hr. Gd(III) chelates demonstrate enhanced cell relaxivity
in vitro. The images were obtained at 9.4 T, field of view = 1.5 cm, TE = 10 ms, TR = 200 ms (50 mM), TE = 10.2 ms, TR 600 ms (500 mM).
(B) T1 data of cells incubated with 50, 150, and 500 mM 1 and 2 (T1 data were taken at 9.4 T, 20
C).absorption and the generation of a transcription complex.
Evidence of transcriptional regulation is supported by the
high level of luciferase activity generated by compound 2
in the PRE transcription assay. The conjugate-induced
transcription provides evidence of cellular permeability,
receptor-mediated retention, and a lack of toxicity. Cellu-
lar transcription suggests that these contrast agents may
be useful for obtaining images long after traditional agents
that are readily excreted. Future studies must be
completed to investigate the cell-specific retention of
these contrast agents in vivo, where the effects of metab-
olism and tissue distribution will critically determine cell
specificity.Chemistry & Biology 14,Progesterone-based contrast agents provide magnetic
resonance signal enhancement inside breast cancer cells.
The T1 effects of compound 2 were substantially changed
at 150 mM in MDA-MB-231 cells both with and without
receptor. Incubating the cells with higher doses of the
contrast agent did not produce additional signal enhance-
ment. Compound 1 was expected to produce a greater tr
effect because it has the highest binding affinity for the
receptor and the slowest rotation of the Gd(III) chelate
due to the absence of the six-carbon spacer. However,
membrane permeability of 1 was significantly lower even
at the highest concentration (500 mM) and failed to en-
hance MR contrast in vitro. Compound 2 showed high824–834, July 2007 ª2007 Elsevier Ltd All rights reserved 831
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Progesterone-Modified MRI Contrast Agentscellular accumulation; however, differences in the amount
of accumulation inside cells between PR-positive and
PR-negative were insignificant, thereby creating MR
images with the same signal intensity. The changes in T1
using relatively low doses of contrast agent indicate that
these newly synthesized compounds are viable contrast
agents that can be utilized in low doses.
In conclusion, a series of progesterone-modified Gd(III)
chelate conjugates was synthesized to generate contrast
agents that accumulate intracellularly and interact with a
biological target highly relevant for cancer prognosis. The
chelates varied in linker length and charge, and we have
identified compound 2 as the most efficient agent for pro-
gesterone receptor binding and intracellular accumulation.
The aliphatic carbon linker between the steroid and the
Gd(III) chelate dramatically improved cellular permeability
while retaining transcriptional activation of the progester-
one responsive element without toxicity. Our results
show that changing the modification site from 3-keto to
21-hydroxyl enhanced the binding affinity approximately
100-fold as compared to a previously reported RU-486-
modified contrast agent [23]. The observed relaxivity of
the contrast agent in mammary cells was significant.
SIGNIFICANCE
Noninvasive means of determining the steroid recep-
tor profile of breast cancers will improve diagnosis
and treatment of disease. An ideal imaging agent will
enter the cell, interact with its biological target, and
specifically increase relaxivity to allow for proper MR
image acquisition. The first generation of progester-
one-based gadolinium contrast agents was devel-
oped to image hormone-responsive tumors using
MRI by taking advantage of the interaction intracellu-
larly with the receptor. A novel chemical synthesis ap-
proachwas utilized to develop progesterone-modified
gadolinium agents. In this study, progesterone gadoli-
nium contrast agents were characterized and found to
interact with progesterone receptors, enter breast
cancer cells, and significantly enhance MRI contrast.
Therefore, future studies will determine whether these
agents will be useful for specifically marking hormone
receptor-expressing cells in both in vitro and in vivo
animal systems. The contrast agents present the op-
portunity to image the location and hormone status
of breast tumors.
EXPERIMENTAL PROCEDURES
Synthesis
Compounds 1–4were synthesized by following the pathway described
in Figure 2. Detailed synthetic procedures and spectroscopic data are
available in the Supplemental Data.
Octanol-Water Partition Coefficient Measurements
Octanol-water partition coefficients were obtained by dissolving 5–
7 mg of each compound (1–4) into mixtures of 500 ml water and
500 ml 1-octanol. The resulting mixture was shaken vigorously for
2 hr on a Lab-Line lab rotator (model 1304; Lab-Line, Dubuque, IA,832 Chemistry & Biology 14, 824–834, July 2007 ª2007 ElsevieUSA). The solvent layers were allowed to separate, and 400 ml of
each layer was removed. The solvent was removed under reduced
pressure, and the mass of material from each layer was measured.
The reported values are for the mass of compound in the 1-octanol
layer divided by the mass of compound in the water layer. Octanol-
water partition coefficient measurements were repeated in triplicate.
Relaxivity Measurements
Relaxivity measurements were acquired by taking the slope of a plot of
T1
1 versus concentration. The longitudinal water proton relaxation
time (T1) at 59.97 MHz was measured using a Bruker mq60 NMR ana-
lyzer (Bruker Canada, Milton, ON, Canada). A 4 mM stock solution of
each compound in deionized water was diluted to give 500 ml each
of six concentrations for each run: 0, 0.125, 0.25, 0.5, 1.0, and
2.0 mM. For 3, a 1 mM stock solution in deionized water was diluted
to give 250 ml each of six concentrations for each run: 0, 0.001,
0.005, 0.01, 0.05, and 0.1 mM. The T1 of each concentration was de-
termined using an inversion recovery pulse sequence with appropriate
recycle delays. The resulting curves were fit to a monoexponential
function to obtain T1. All lines fit with r
2 > 0.998, and the measurements
were performed in duplicate.
Progesterone Receptor Binding Assay
The progesterone receptor A ligand binding domain (amino acids 675–
933) fused to GST (PR-LBD-GST; 80 nM), a fluorescently tagged PR
ligand (fluoromone green PL; 4 nM), and either progesterone (1 mM)
or compound 1–4 (several concentrations) were incubated in PR
screening buffer with 4 mM dithiothreitol (DTT) in a total volume of
100 ml for 1 hr at room temperature according to the manufacturer’s
protocol (Invitrogen, Carlsbad, CA, USA). Each sample was performed
in at least triplicate using the Beacon 2000 fluorescence polarization
analyzer (Invitrogen) located in the Northwestern University Keck Facil-
ity. The machine was used in static mode, batch blank, no delay, with
an average of 1 read per cycle, at 22C. An average of three samples
containing only buffer and PR-LBD-GST with no fluorescent PL was
used as the blank to eliminate background signal from the protein or
buffer. A sample with no competitor was used to determine 100%
binding capacity of the PR-LBD-GST for the PL ligand.
Progesterone Response Element-Luciferase Transcriptional
Activation
T47D breast cancer epithelial cells (American Type Culture Collection,
Manassas, VA, USA) were cultured in phenol red-free RPMI (Life Tech-
nologies, Gaithersburg, MD, USA) supplemented with 10% fetal
bovine serum (FBS) (Invitrogen) and 1% antimycotic/antibiotic (Invitro-
gen) and incubated at 37C, under 5% CO2. Cells were plated 1 day
before transfection in 24-well plates and transiently transfected in
Opti-MEM (Invitrogen) with PRE-luciferase (a kind gift from Ken Kor-
ach, NIEHS, NIH). Cells were then treated with serum-free media
and vehicle (DMSO), progesterone, and progesterone-modified con-
trast agents for 24 hr. To measure luciferase production, cells were
lysed in GME buffer (25 mM glycylglycine [pH 7.8], 15 mM MgSO4,
4 mM EGTA, 1 mM DTT, and 1% Triton X-100) and lysates were added
to assay buffer (GME buffer, 16.5 mM KPO4, 2.2 mM ATP, and 1.1 mM
DTT). Luciferase activity was measured for 30 s using an AutoLumat
(Berthold Technologies, Oak Ridge, TN, USA). A separate protein de-
termination using the BCA kit (Pierce, Rockford, IL, USA) was used to
normalize protein levels that might differ from treatment with hormone.
Mammary Cell Progesterone-Gd(III) Cellular Uptake
Progesterone receptor-positive cells, T47D, and progesterone recep-
tor-negative cells (MDA-MB-231) were used to determine uptake effi-
ciency of progesterone-modified contrast agents into hormone recep-
tor-expressing cells. MDA-MB-231 breast cancer epithelial cells
(American Type Culture Collection) were cultured in phenol red-free
DMEM/F12 (Life Technologies) supplemented with 10 mg/ml insulin,
5% charcoal dextran-stripped FBS (Cellgro, Herndon, VA, USA), 1%
glutamax, and 1% antimycotic/antibiotic (Invitrogen) and incubatedr Ltd All rights reserved
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next day were moved into serum-free media for 24 hr before treatment
with compound 1–4. To determine the dose of PR-Gd necessary to ac-
cumulate in the cells, the following doses were incubated with cells for
24 hr: 0, 0.05, 0.5, 5, and 50 mM. In order to determine the optimal incu-
bation time, 50 mM PR-Gd compounds was incubated with the cells for
the following time periods: 0, 1, 2, 4, and 24 hr. Data were analyzed by
counting the cells, followed by lysis and ICP-MS. For leaching experi-
ments, contrast agents were incubated with the cells for 4 hr, removed,
and rinsed with PBS. At each time point after the initial rinse, cell media
were removed, rinsed, and replaced with serum-free media and then
collected at 15 min, 1, 2, 4, 6, 24, 48, and 72 hr. The cells were also col-
lected by trypsinization and lysed to compare intracellular content of
the cells with that which leached into the media.
Synchrotron Radiation X-Ray Fluorescence Analysis
Thereceptor-positiveand-negativecellswere incubatedwith1and2 for
24 hr prior to analysis. The cells were washed and collected by following
the same procedure as described above. Approximately 15 ml of each
suspension was applied to Formvar-coated gold grids with a sterile
glass Pasteur pipette for 1 min and the excess supernatant was re-
moved. This was followed by addition of approximately 15 ml of room
temperature ethanol, removal of the ethanol, and drying at ambient tem-
perature for 15hr.Thecell coveragewasapproximately15–30cells/grid.
Electron microscope grids with cells were mounted onto a kinematic
specimen mount for both visible light and X-ray fluorescence micros-
copy. The samples were examined under a light microscope (Leica
DMXRE, Solms, Germany), and the cells to be scanned with SR-XRF
were placed on the grid relative to a reference point using a high spatial
resolution motorizedx/ystage (Ludl Bioprecision,Hawthorne,NY,USA).
X-Ray Fluorescence Microscopy
Synchrotron scanning X-ray fluorescence microscopy was carried out
at the 2-ID-E beamline of the Advanced Photon Source at Argonne Na-
tional Laboratory (Argonne, IL, USA). Hard X-rays (10 keV) from an undu-
lator source were monochromatized using a single-bounce Si < 111 >
monochromator. The energy was selected to allow for efficient excita-
tion of the Gd L lines and to enable the detection of the Zn K lines. A
Fresnel zone plate (320 mm diameter, focal length f = 250 mm, Xradia,
Concord, CA, USA) was used to focus the monochromatic X-ray beam
to a spot size of approximately 0.3 3 0.3 mm2 on the specimen. The
sample was raster scanned through the beam at room temperature un-
der a helium atmosphere. At each scan position, a full fluorescence
spectrum was acquired using an energy dispersive germanium detec-
tor (Ultra-LEGe; Canberra, Meriden, CT, USA). Elemental content was
determined by comparison of fitted sample spectra with National
Bureau of Standards thin film standards 1832 and 1833 (National
Institute of Standards and Technology, Gaithersburg, MD, USA) using
MAPS software supplemented with fitting of fluorescence spectra at
each pixel.
T1-Weighted Image Acquisition
The receptor-positive cells (T47D and MDA-MB-231 transfected with
PRA) and -negative cells (MDA-MB-231) were incubated with no agent
or 50, 150, and 500 mM compound 1 and 2 for 24 hr at 37C. Cells were
loaded into capillary tubes (1 mm diameter) as trypsin suspensions. All
MR data were collected at ambient temperature in a General Electric/
Bruker Omega 400WB 9.4 T magnet (83 mm bore size) fitted with
Accustar shielded gradient coils (Bruker, Westmont, IL, USA). Spin-
lattice relaxation times (T1) were measured using an inversion recovery
pulse sequence, and images were acquired using a T1-weighted spin-
echo pulse sequence with a repetition time (TR) of 1002000 ms and
an echo time (TE) of 1010.2 ms.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
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